Rett Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Rett Syndrome - Pipeline Review, H2 2016

Rett Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Rett Syndrome - Pipeline Review, H2 2016
Published Oct 29, 2016
122 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome Pipeline Review, H2 2016, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape.

Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rett Syndrome Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 3, 8, 3 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively for Rett Syndrome.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeli

  
Source:
Document ID
GMDHC8597IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures62
Introduction81
  Global Markets Direct Report Coverage81
Rett Syndrome Overview91
Therapeutics Development102
  Pipeline Products for Rett Syndrome Overview101
  Pipeline Products for Rett Syndrome Comparative Analysis111
Rett Syndrome Therapeutics under Development by Companies122
Rett Syndrome Therapeutics under Investigation by Universities/Institutes141
Rett Syndrome Pipeline Products Glance154
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
  Unknown Stage Products181
Rett Syndrome Products under Development by Companies191
Rett Syndrome Products under Investigation by Universities/Institutes201
Rett Syndrome Companies Involved in Therapeutics Development2117
  Anavex Life Sciences Corp.211
  ArmaGen Inc.221
  Edison Pharmaceuticals, Inc.231
  Eloxx Pharmaceuticals, Ltd.241
  GW Pharmaceuticals Plc251
  Mitochon Pharmaceuticals, Inc.261
  Mitsubishi Tanabe Pharma Corporation271
  Neuren Pharmaceuticals Limited281
  Neurolixis Inc.291
  Newron Pharmaceuticals S.p.A.301
  OPKO Health, Inc.311
  Oryzon Genomics SA321
  PharmatrophiX, Inc.331
  Raptor Pharmaceutical Corp.341
  Recursion Pharmaceuticals, LLC351
  Sage Therapeutics, Inc.361
  Ultragenyx Pharmaceutical Inc.371
Rett Syndrome Therapeutics Assessment389
  Assessment by Monotherapy Products381
  Assessment by Target392
  Assessment by Mechanism of Action412
  Assessment by Route of Administration432
  Assessment by Molecule Type452
Drug Profiles4763
  amlexanox Drug Profile471
  ANAVEX-273 Drug Profile489
  Bryostatin-1 Drug Profile574
  CPT-157633 Drug Profile611
  cysteamine DR Drug Profile628
  desipramine hydrochloride Drug Profile701
  ELX-02 Drug Profile711
  fingolimod hydrochloride Drug Profile726
  Gene therapy to Activate MECP2 for Rett Syndrome Drug Profile781
  LM-22A4 Drug Profile791
  MP-101 Drug Profile801
  NLX-101 Drug Profile811
  Oligonucleotide For Rett Syndrome Drug Profile821
  ORY-2001 Drug Profile832
  Recombinant Protein for Rett Syndrome Drug Profile851
  REV-003 Drug Profile861
  SAGE-217 Drug Profile872
  sarizotan hydrochloride Drug Profile893
  Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile921
  Small Molecules for Rett Syndrome Drug Profile931
  Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome Drug Profile941
  trofinetide Drug Profile956
  UX-007 Drug Profile1015
  vatiquinone Drug Profile1064
Rett Syndrome Dormant Projects1101
Rett Syndrome Product Development Milestones11110
  Featured News &Press Releases1111
    Jun 24, 2016: Neuren presents at the Rettsyndrome.org 2016 Research Symposium1111
    Jun 22, 2016: Neuren receives grant of new Australian patent for trofinetide to treat Autism Spectrum Disorders1111
    Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X Autism-Related Disorders1121
    May 20, 2016: Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome1131
    May 17, 2016: Mitochon Pharmaceuticals Raises $1.6M for Clinical Stage Development1131
    Apr 07, 2016: First subject commences Neuren s pediatric Rett syndrome Phase 2 trial1131
    Feb 25, 2016: Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome1141
    Oct 13, 2015: Rettsyndrome.org confirms financial support for Neuren s clinical trials of trofinetide1151
    Oct 12, 2015: Neuren receives Notice of Allowance for new US patent covering the use of trofinetide to treat Rett syndrome1161
    Aug 14, 2015: trofinetide confirmed as the International Nonproprietary Name for Neuren s NNZ-25661161
    Aug 13, 2015: Neuren confirms orphan drug designation in Europe for Rett syndrome and Fragile X syndrome1161
    Jul 29, 2015: Neuren reports progress in orphan drug programs1171
    Nov 12, 2014: Neuren s NNZ-2566 successful In Demonstrating Clinical Benefit In Rett syndrome Phase 2 trial1181
    Dec 24, 2012: Neuren Pharma Receives FDA Approval For Phase II trial Of NNZ-2566 In Rett Syndrome1191
    May 17, 2012: Neuren Holds Pre-IND Meeting On Proposed Rett Syndrome Clinical Trials With FDA1201
Appendix1212
  Methodology1211
  Coverage1211
  Secondary Research1211
  Primary Research1211
  Expert Panel Validation1211
  Contact Us1211
  Disclaimer1221

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Rett Syndrome - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rett-Syndrome-Pipeline-Review-H2-2016-2088-16713>
  
APA:
Global Markets Direct - Market Research. (2016). Rett Syndrome - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rett-Syndrome-Pipeline-Review-H2-2016-2088-16713>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.